Biological E partners with Bavarian Nordic to expand access to Chikungunya Vaccine in low- and middle-income countries.

This partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya ...

Hyderabad: Biopharma player Biological E (BE) entered into a strategic partnership with Danish vaccine maker Bavarian Nordic ...

COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA ® for active ...

Several observations point toward the possibility of a vaccine development strategy ... and MVA Liver stage IIa LSA1 WRAIR, GSK, MVI Recombinant protein, AS02/AS01 Liver stage I/IIa LSA3 Institut ...

Hyderabad: Biological E. Limited has announced a strategic partnership with Bavarian Nordic A/S to expand access to Bavarian ...

Biological E (BE) has partnered with Bavarian Nordic to produce the Chikungunya vaccine, VIMKUNYA CHIKV VLP, for low and ...

The partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine ...

HCV vaccines ... proteins Treatment-naive HCV patients Decrease of HCV viral load associated with a boost of HCV-specific T-cell response [108,205] Intercell AG IC41: poly-l-arginine-adjuvanted ...

Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya ...